Recently, Regeneron ( REGN -1.41%) entered an agreement to acquire 23andMe for $256 million, which is a tiny fraction of its ...

I’ll admit to being surprised initially by the mid-month announcement that Regeneron Pharmaceuticals planned to buy out of ...

Genetic testing company 23andMe had 15 million consumers who turned to them to learn more about their ancestry and understand ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

If it gets a green light, as expected, the company could gain access to genetic data from more than 15 million 23andMe customers worldwide. Is Regeneron a good stock to buy now in light of a ...

Regneron stock crashed today following disappointing COPD trials data. Here's what makes REGN shares worth buying on the ...

The strategic move is aimed at integrating automated, high-throughput gene synthesis into Regeneron's in-house laboratories.

Sanofi (SNY) stock and Regeneron (REGN) stock fell after the companies reported mixed Phase 3 results for their COPD therapy ...

As staffing levels shrink and workloads grow, a troubling trend is taking shape in the American workplace.A new report shows ...

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

Regeneron (NASDAQ:REGN) shares fell ~18% to reach a new 52-week low as a Phase 3 trial failure for its antibody therapy itepekimab, developed with Sanofi (SNY) for a lung disorder known as chronic ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.